Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/305% below fair value
$2.83+0.10 (+3.86%)
Close on Nov 18, 2026Market cap $1.51BP/E –Yield –
Recursion Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Recursion Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$352.27M. For fiscal 2025 it was -$378.28M. The highest annual figure on record is -$51.23M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$378.28M | – |
| FY2024 | Dec 31, 2024 | -$372.87M | – |
| FY2023 | Dec 31, 2023 | -$299.74M | – |
| FY2022 | Dec 31, 2022 | -$120.58M | – |
| FY2021 | Dec 31, 2021 | -$198.41M | – |
| FY2020 | Dec 31, 2020 | -$51.23M | – |
| FY2019 | Dec 31, 2019 | -$60.95M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$105.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$81.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.32M | – |
| Q3 FY2025 | Sep 30, 2025 | -$117.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$79.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$133.79M | – |
| Q4 FY2024 | Dec 31, 2024 | -$116.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$63.79M | – |
| Q2 FY2024 | Jun 30, 2024 | -$83.40M | – |
| Q1 FY2024 | Mar 31, 2024 | -$108.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$76.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$73.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$71.44M | – |
| Q1 FY2023 | Mar 31, 2023 | -$78.49M | -207.5% |
| Q4 FY2022 | Dec 31, 2022 | -$52.73M | – |
| Q3 FY2022 | Sep 30, 2022 | -$62.80M | – |
| Q2 FY2022 | Jun 30, 2022 | -$78.10M | – |
| Q1 FY2022 | Mar 31, 2022 | $73.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$65.62M | -1443.1% |
| Q3 FY2021 | Sep 30, 2021 | -$42.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -$39.87M | – |
| Q1 FY2021 | Mar 31, 2021 | -$50.17M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$20.28M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.33M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.50M | – |
See a number that looks wrong?